Print This PageEmail this Page


The Monarch external Trigeminal Nerve Stimulation (eTNS) System treats ADHD non-invasively with signals delivered to the brain via the trigeminal nerve on the forehead.

The Monarch eTNS system received CE Mark approval and is now available in the European Union. eTNS is indicated as a treatment for ADHD in patients ages 7 and older. If you are interested in trying eTNS for yourself or a loved-one, fill out our contact form and a NeuroSigma representative will contact you.

What is ADHD?

Attention Deficit Hyperactivity Disorder or "ADHD" is defined by problems with attention, hyperactivity and impulsivity. ADHD is estimated to affect up to 9.5% of school age children and 4.4% of adults. While the condition is often first diagnosed in childhood, symptoms persist into adolescence in the majority of patients, and impairments are present in adulthood even when symptoms may be reduced.

Treating ADHD with eTNS

The eTNS system was developed and tested by doctors at the University of California, Los Angeles (UCLA). Clinical trials have shown it to be safe and effective for treating ADHD. The journal Brain Stimulation published results in 2015 from the first trial of eTNS for the treatment of ADHD in children ages 7–14. Patients receiving eTNS for as little as 4 weeks experienced an average decrease in symptom severity of 44%, according to the study. Subjects enrolled in the trial also showed significant improvements in computer based tests designed to measure attention and focus.

Treatment of ADHD with eTNS is easy and convenient. Patients use the system in the comfort of their own home. The device is about the size of a cell phone. A wire connects the device to a small patch that adheres to a patient's forehead, just above the eyebrows. Patients typically describe stimulation as a tingling sensation and most choose to deliver the therapy at night while they sleep. eTNS is approved for the treatment of Attention Deficit Hyperactivity Disorder in patients 7 and older in the European Union.

Change in ADHD Symptoms After 8 Weeks of eTNS

24 Children with ADHD were enrolled to receive 8 weeks of eTNS. Subjects had an average decrease in symptom severity of 44% at the end of the trial as measured by the ADHD Rating Scale (ADHD-RS). These results were statistically significant (p < 0.01).


To obtain a Monarch eTNS system, please contact us and a NeuroSigma representative will be in touch soon.

Back to Top